p53 Gain-of-Function Mutation Induces Metastasis via BRD4-Dependent CSF-1 Expression

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metastasis

Background:

• TP53 mutations are common in esophageal squamous cell carcinoma (ESCC) and linked to metastasis.
• Colony-stimulating factor-1 (CSF-1) expression is elevated in metastatic ESCC lesions, particularly in a p53-R172H-dependent manner.

Purpose of the Study:

• To investigate the role of the p53-R172H-dependent CSF-1 signaling pathway in ESCC lung metastasis.
• To identify therapeutic targets within this pathway for treating ESCC.

Main Methods:

• Analysis of CSF-1 expression in metastatic ESCC lesions.
• Investigating the interaction between p53, BRD4, and the Csf-1 promoter.
• Assessing the effect of BRD4 inhibition on tumor invasion and metastasis in vivo.
• Measuring circulating CSF-1 levels after BRD4 inhibition.

Main Results:

• p53-R172H-dependent CSF-1 signaling promotes tumor cell invasion and lung metastasis via Stat3 phosphorylation and epithelial-to-mesenchymal transition (EMT).
• p53 directly binds to the Csf-1 promoter, and BRD4 facilitates this interaction to regulate Csf-1 transcription.
• Inhibition of BRD4 significantly reduces ESCC tumor invasion, lung metastasis, and circulating CSF-1 levels.
• The identified BRD4-CSF-1 axis correlates with patient survival and tumor stage.

Conclusions:

• A novel p53-R172H-dependent BRD4-CSF-1 axis drives ESCC lung metastasis.
• Targeting this axis offers a promising therapeutic strategy for managing ESCC metastasis.